Pioglitazone Improved Insulin Sensitivity and First Phase Insulin Secretion Among Obese and Lean People with Diabetes: A Multicenter Clamp Study

ConclusionA 16-week treatment of PIO significantly increased insulin sensitivity and β-cell function in the lean group as well as in the obese group among Chinese T2DM patients, demonstrating that both lean and obese diabetic adults would profit from PIO.Trial registrationThe ChiCTR registry number is ChiCTR-OPC-17011571.FundingTakeda Pharmaceutical Co. Ltd. and Pfizer Pharmaceutical Co. Ltd.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research